🟢 Telix Pharmaceuticals is trading 7% up in pre-market after FDA approval of Pixclara for glioma imaging

Telix Pharmaceuticals is trading 7.17% up in pre-market at $12.10 after U.S. FDA approval of Pixclara.

• Pixclara is indicated for PET imaging to differentiate recurrent or progressive glioma from treatment-related changes in adults and children.
• It is described as the first FDA-approved FET-PET and only FDA-approved radiopharmaceutical imaging drug for glioma.
• Telix presents at the Morgan Stanley Global Healthcare Conference on September 14; the announcement did not explicitly attribute the pre-market move to share-price activity.